Industry-Sponsored Research Week

UC-Irvine and Diomics Corp. announce sponsored research agreement focused on islet transplants


By David Schwartz
Published: January 14th, 2020

The University of California, Irvine (UCI) and Diomics Corporation have entered a sponsored research agreement that aims to improve islet transplantation for patients living with type 1 diabetes. The program will be run in the lab of Dr. Jonathan Lakey, director of UCI’s Clinical Islet Program.

The current method for islet transplantation requires invasive, difficult, and time consuming surgeries that create stress and risk for both the patients and the islets. To circumvent these issues, the research will be focusing on cell encapsulation using a Diomics technology that overcomes limitations of polycaprolactone (PCL) polymer, which degrades too slowly and has poor cell adhesion qualities.

Dr. Lakey is a world-class expert on cell therapies including pancreatic islets and stem cells and pioneered novel methods for implantation of pancreatic islets in diabetes patients. “I am thrilled for the opportunity to work with Diomics and examine this novel and important proprietary biomaterial,” :Lakey said.

Diomics recently filed provisional patents with claims broadly covering its proprietary polymer technology, Diomat™, for applications in cell therapy, transdermal and related drug delivery methods. The Diomics-sponsored research at UCI will develop data that can be leveraged in clinical trials for improved islet transplantation therapy, potentially restoring natural insulin production for type 1 diabetes patients.

Source: BioSpace

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment